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Abstract
BACKGROUND: Direct stenting without pre-dilation or post-dilation has been advocated for 
saphenous vein graft percutaneous coronary intervention to decrease the incidence of distal 
embolization, periprocedural myocardial infarction, and target lesion revascularization.
METHODS: We performed a post hoc analysis of patients enrolled in the DIVA (Drug-Eluting 
Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty; ) prospective, double-blind, 
randomized controlled trial. Patients were stratified into stent-only and balloon-stent groups. 
Primary end point was 12-month incidence of target vessel failure (defined as the composite of 
cardiac death, target vessel myocardial infarction, or target vessel revascularization). Secondary 
end points included all-cause death, stent thrombosis, myocardial infarction, and target lesion 
revascularization during follow-up.
RESULTS: Of the 575 patients included in this substudy, 185 (32%) patients underwent stent-
only percutaneous coronary intervention. Patients in the stent-only versus balloon-stent group had 
similar baseline characteristics and similar incidence of target vessel failure at 12-months (15% 
versus 19%; hazard ratio, 1.34 [95% CI, 0.86–2.08]; P=0.19). During long-term follow-up 
(median of 2.7 years), the incidence of definite stent thrombosis (1% versus 5%; hazard ratio, 9.20 
[95% CI, 1.23–68.92]; P=0.0085), the composite of definite or probable stent thrombosis (5% 
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versus 11%; hazard ratio, 2.52 [95% CI, 1.23–5.18]; P=0.009), and target vessel myocardial 
infarction (8% versus 14%; hazard ratio, 1.92 [95% CI, 1.08–3.40]; P=0.023) was lower in the 
stent-only group. Multivariable analysis showed that a higher number of years since coronary 
artery bypass grafting and >1 target saphenous vein graft lesions were associated with increased 
target vessel failure during entire follow-up, while preintervention Thrombolysis in Myocardial 
Infarction-3 flow was protective.
CONCLUSIONS: In patients undergoing percutaneous coronary intervention of de novo 
saphenous vein graft lesions, there was no difference in target vessel failure at 12 months and 
long-term follow-up in the stent-only versus the balloon-stent group; however, the incidence of 
stent thrombosis was lower in the stent-only group, as was target vessel myocardial infarction.
REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: .
Keywords
angioplasty; dilatation; incidence; myocardial infarction; stents
Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) comprises ≈6% 
of total PCIs performed in the United States. Whereas pre-dilation and post-dilation are 
recommended in native coronary PCI1 to facilitate stent delivery and optimize stent 
apposition and expansion, retrospective studies have shown an association between direct 
stenting and a lower incidence of periprocedural myocardial infarction or target lesion 
revascularization in SVG lesions,2–7 possibly due to lower risk for distal embolization.5 
Similarly, post-dilatation of SVG lesions could lead to plaque protrusion through the stent 
struts (cheese-grater effect) leading to distal embolization and periprocedural myocardial 
infarction, which has been associated with higher mortality.4
We examined the frequency of adjunctive balloon angioplasty during stenting of SVG 
lesions and associated clinical outcomes in patients enrolled in the DIVA trial (Drug-Eluting 
Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty).8 We hypothesized 
that the stent-only group will have better outcomes compared with the balloon-stent group.
METHODS
The design of the DIVA trial has been published.9 Briefly, DIVA was a multicenter, 
randomized-controlled trial conducted at 25 Veterans Affairs medical centers that 
randomized patients undergoing SVG PCI to either bare-metal stents or drug-eluting stents. 
The trial was funded by the Department of Veterans Affairs’ Cooperative Studies Program. 
Veterans Affairs’ Central Institutional Review Board approval was obtained. The authors 
declare that all supporting data are available within the article.
Patients
Patients who signed an informed consent were at least 18 years of age and were found to 
have at least one de novo 50% to 99% stenosis of an SVG with diameter 2.25 to 4.5mm were 
eligible to be randomized. Intent to use an embolic protection device was required. Patients 
were excluded if any surgery was planned within 12 months; presented with an ST-segment 
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elevation MI; the culprit SVG stenosis was in the last remaining conduit; had previous PCI 
of the target SVG within the preceding 12 months; had hemorrhagic diatheses, or refused to 
receive blood transfusions; required anti-coagulation and were considered high risk of 
bleeding with triple anticoagulation/antiplatelet therapy; had recent positive pregnancy test, 
breast-feeding, or possibility of a future pregnancy; had coexisting conditions that limited 
life expectancy to <12 months; had a history of allergic reaction or significant sensitivity to 
any drug or metal included in drug-eluting stents; were allergic to clopidogrel and did not 
present with acute coronary syndrome at sites that used blinded study medication; or 
participating in another interventional randomized trial. DIVA study did not show any 
difference in ischemic outcomes between bare-metal stent and drug-eluting stents.8
Assessment of Groups
The balloon-stent group included patients who underwent balloon angioplasty in the SVG 
target lesion before and/or after (either bare metal or drug-eluting) stent implantation. The 
stent-only group included patients who did not undergo balloon angioplasty either before or 
after stent implantation.
PCI was performed using standard techniques per operator preference. The study did not 
provide any guidance on use of balloon angioplasty.
Follow-Up and Outcomes
Patients were followed every 3 months during the first year and every 6 months thereafter.
The primary end point of the DIVA trial and this substudy was the 12-month incidence of 
target vessel failure (TVF), defined as the composite of cardiac death, target vessel 
myocardial infarction (MI), or target vessel revascularization (TVR). Secondary end points 
included the 12-month incidence of all-cause death, death due to cardiac or unknown cause, 
MI during follow-up, MI due to target SVG (or indeterminate vessel) during follow-up, MI 
due to nontarget vessel, any revascularization or target vessel revascularization (PCI or 
CABG [coronary artery bypass grafting]), target lesion revascularization, nontarget vessel 
revascularization, target lesion failure (composite of cardiac or unknown death, target vessel, 
or target lesion revascularization), stent thrombosis, stroke, postprocedural bleeding, and 
patient-oriented composite end point (any death, any MI, or TVR).
Definitions of the study end points have been published.9 Stent thrombosis was defined 
using Academic Research Consortium as definite, probable, or possible. Periprocedural MI 
was defined as >3× upper limit of normal CK-MB increase in patients with normal baseline 
CK-MB and >50% increase in patients with elevated baseline CK-MB.
Statistical Analysis
For this post hoc analysis of DIVA data, we stratified patients into stent-only and balloon-
stent groups. The primary end point was the 12-month incidence of TVF. Nominal variables 
were presented as percentages and compared using the χ2 test and continuous variables were 
presented as mean (SD) or median (interquartile range) and compared using the t-test or 
Wilcoxon rank-sum test, as appropriate. Cumulative incidence curves and log-rank tests 
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were used to compare the 2 groups on the incidence of the primary and secondary clinical 
outcomes. Statistical analyses were performed using SAS 9.2 (SAS institute, Cary, NC).
In addition to the univariate models, Cox proportional hazards models were used to assess 
the effect of balloon usage on TVF in the presence of other covariates assessed at baseline 
(age, diabetes mellitus, number of target lesions, years since most recent CABG, indication 
for PCI, CHF, pre-PCI Thrombolysis in Myocardial Infarction-flow, presence of thrombus, 
and use of embolic protection device). A 2-sided P value of 0.05 from the log-rank test was 
used as the level of significance for the primary outcome. As a preplanned secondary 




After screening 3482 patients with prior CABG, 597 patients undergoing PCI of a de novo 
50% to 99% SVG stenosis were randomly assigned to receive either bare-metal stent or 
drug-eluting stents between January 2012 and December 2015. After excluding 22 patients 
(17 patients had lesions which did not qualify for inclusion, 4 did not undergo PCI, and 1 
subject who had failed PCI), 575 patients who received a stent in the target SVG were 
included in the present study, of whom 185 (32%) underwent stent-only PCI and 390 (68%) 
underwent balloon-stent SVG PCI.
The baseline demographic, angiographic, and procedural characteristics were similar in the 
stent-only and balloon-stent groups (Tables 1 and 2). The target SVG lesion location was 
more frequently in the SVG body in the stent-only group. In the balloon-stent group, a 
second balloon was used in 156 patients and was larger than the first balloon. Compared 
with the stent only group, the incidence of periprocedural MI was numerically higher in the 
balloon-stent group.
Study Outcomes
The 12-month incidence of TVF was 15% in the stent-only group and 19% in the balloon-
stent group (hazard ratio for balloon-stent group, 1.34 [95% CI, 0.86–2.08]; P=0.19; Table 
3). The incidence of target vessel myocardial infarction and definite or probable stent 
thrombosis was higher in the balloon-stent group (Figure).
The incidence of TVF during the entire duration of follow-up was 38% in the stent-only 
group versus 33% in the balloon-stent group (hazard ratio, 0.89 [95% CI, 0.67–1.19]; 
P=0.43; Table 4). The incidence of definite and definite/probable stent thrombosis and the 
incidence of target vessel myocardial infarction was higher in the balloon-stent group (Table 
4). Medication usage was similar in the 2 study groups (Table 5).
Multivariable analysis showed that adding group identifier (stent-only versus balloon-stent) 
to the proportional hazard model with selected participant and graft characteristics did not 
significantly increase the ability to predict TVF during the entire follow-up period, though 
number of years since CABG and >1 target SVG lesion were associated with increased TVF 
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during entire follow-up, while preintervention Thrombolysis in Myocardial Infarction-3 flow 
was protective. Using this model, adjunctive balloon angioplasty, presence of thrombus, or 
use of embolic protection device were not associated with TVF during the entire follow-up 
period (Table 6).
DISCUSSION
The main finding of our study is that in patients undergoing PCI of de novo SVG lesions, 
use of adjunctive balloon angioplasty (performed in two thirds of the study patients) was 
associated with higher incidence of stent thrombosis and target vessel MI during follow-up 
as compared with the stent-only group.
There are several potential explanations for the higher incidence of ST in the stent-balloon 
group. First, lesions treated with adjunctive balloon angioplasty were more likely to be 
located at the aortic or distal anastomosis, which may be more difficult to expand, as aorto-
ostial lesions are more likely to be calcified10 and both aorto-ostial and distal anastomotic 
lesions are affected by postsurgical fibrotic changes.11 In contrast, SVG body lesions more 
commonly include softer, friable plaque and might require less lesion preparation with 
predilatation.12 Second, balloon angioplasty may lead to distal embolization, which can lead 
to myocardial injury in the supplied myocardium and possibly impair subsequent myocardial 
flow. Indeed, there was a trend for higher incidence of periprocedural myocardial infarction 
in the balloon stent group4 (Table 2). Third, balloon angioplasty may cause more extensive 
SVG wall injury, potentially triggering formation of neointima and neoatherosclerosis that 
could form the nidus for subsequent stent thrombosis and/or restenosis. Although not 
observed in our study, a prior retrospective study showed higher 12-month incidence of 
target lesion revascularization at 1 year with the use of balloon angioplasty as compared 
with direct stenting during SVG PCI (34% versus 21%; P=0.02).5 Fourth, there may be 
unmeasured differences in lesion composition and overall PCI approach in the stent-only 
versus stent-balloon groups that contribute to subsequent outcomes. The Kaplan-Meier 
curves for stent thrombosis continued to separate after 12 months of follow-up (Figure), 
suggesting that the factors underlying the aforementioned differences have a long-lasting 
impact, hence are unlikely to be purely related to differences in periprocedural 
complications.
While our study supports stenting without pre-or post-dilation in SVG PCI, many SVG 
lesions may still require either predilation to create a channel in a severely stenosed SVG to 
deploy an embolic protection device distally or post-dilation to optimize stenting result. 
Compared with native vessel PCI, a lower incidence of calcification (reported in <20% of 
SVG lesions) further decreases the need for predilation compared with native vessel PCI.13 
Finally, slight stent under-sizing may have no adverse impact in short- or long-term 
outcomes and may actually be beneficial in SVG PCI,14 although what constitutes an 
acceptable result remains to be determined. Use of intravascular imaging could facilitate 
assessment of SVG lesions and guide PCI.13 Compared with SVG-PCI, native coronary PCI 
has demonstrated lower rates of TVF and therefore should be preferred when feasible.15
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Our study has limitations. It is a post hoc analysis of a prospective randomized-controlled 
trial, with all associated limitations. Data on the timing of balloon angioplasty (before or 
after stent placement or both) were not available. As is typical in VA studies, nearly all study 
participants were men, limiting extrapolation of the results to women, although the majority 
of patients undergoing PCI after CABG are men.
CONCLUSIONS
Adjunctive balloon angioplasty during SVG PCI is associated with higher incidence of stent 




DIVA trial (Drug-Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty) was funded by the 
Department of Veterans Affairs’ Cooperative Studies Program.
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DIVA Drug-Eluting Stents Versus Bare Metal Stents in Saphenous Vein 
Graft Angioplasty
EPD embolic protection device
MI myocardial infarction
PCI percutaneous coronary intervention
PMI periprocedural myocardial infarction
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• Compared with direct stenting, adjunctive balloon angioplasty during stenting 
of saphenous vein grafts leads to an increase in distal embolization and 
periprocedural myocardial infarction.
WHAT THE STUDY ADDS
• This substudy from a large, multicenter randomized controlled trial 
demonstrated that when compared with stenting alone, adjunctive balloon 
angioplasty during stenting of saphenous vein grafts leads to an increase in 
stent thrombosis and an increase in target vessel–related myocardial 
infarction.
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Kaplan-Meier curves during the entire duration of follow-up. A, Target vessel failure; B, 
target vessel/indeterminate myocardial infarction (MI); C, definite or probable stent 
thrombosis.
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Table 1.
Baseline Clinical and Demographic Characteristics of the Study Patients
Stent-Only (n=185) Balloon-Stent (n=390) P Value
Age 68.48±7.35 68.65±7.66 0.91
Men, n (%) 183 (99%) 390 (100%) 0.10
Diabetes mellitus, n (%) 111 (60%) 234 (60%) 1.00
Current smoking, n (%) 46 (25%) 83 (21%) 0.34
Hypertension, n (%) 179 (97%) 374 (96%) 0.62
Hyperlipidemia 183 (99%) 376 (96%) 0.09
Indication for PCI, n (%)
 Stable angina 71 (38%) 146 (37%) 0.95
 Unstable angina 57 (31%) 120 (31%)
 NSTEMI 41 (22%) 94 (24%)
 Other 16 (9%) 30 (8%)
Number of diseased coronary vessels, n (%)
 None 0 (0%) 1 (0%) 0.95
 1-vessel 3 (2%) 8 (2%)
 2-vessel 18 (10%) 36 (9%)
 3-vessel 161 (87%) 334 (86%)
 Other 3 (2%) 10 (3%)
Prior MI, n (%) 94 (51%) 210 (54%) 0.50
LVEF, % 49.92±14.82 49.31±12.70 0.39
Congestive heart failure, n (%) 67 (36%) 137 (35%) 0.80
Body mass index (kg/m2) 30.67±5.89 30.44±5.31 0.91
PreIndex PCI estimated GFR (mean) 77.13±24.87 76.96±23.86 0.84
History of atrial fibrillation, n (%) 35 (19%) 70 (18%) 0.78
Peripheral arterial disease, n (%) 33 (18%) 70 (18%) 0.97
GFR indicates glomerular filtration rate; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NSTEMI, non-ST-segment elevation 
myocardial infarction; and PCI, percutaneous coronary intervention.
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Table 2.
Angiographic Characteristics of the Study Patients
Stent-Only (n=185 Subjects and 
248 Lesions)
Balloon-Stent (n=390 Subjects and 
440 Lesions) P Value
Target graft recipient vessel–subject, n (%)
 LAD/diagonal 39 (21%) 86 (22%) 0.51
 Circumflex/OM 69 (37%) 161 (41%)
 RCA/PDA 77 (42%) 143 (37%)
Target graft recipient vessel–lesion, n (%)
 LAD/diagonal 51 (21%) 100 (23%) 0.23
 Circumflex/OM 95 (38%) 188 (43%)
 RCA/PDA 102 (41%) 152 (35%)
BMS–subject, n (%) 91 (49%) 201 (52%) 0.60
BMS–lesion, n (%) 121 (49%) 232 (53%) 0.32
DES–subject, n (%) 94 (51%) 191 (49%) 0.68
 First generation 11 (6%) 12 (3%) 0.10
 Second generation 86 (46%) 179 (46%) 0.89
DES–lesion, n (%) 127 (51%) 210 (48%) 0.38
 First generation 15 (6%) 12 (3%) 0.0312
 Second generation 115 (46%) 198 (45%) 0.73
Embolic protection device used–subject, n (%) 135 (73%) 275 (71%) 0.54
Embolic protection device–lesion, n (%) 178 (72%) 309 (70%) 0.67
SVG target lesion location–subject, n (%)
 Ostial 37 (20%) 104 (27%) 0.0011
 Body 139 (75%) 237 (61%)
 Anastomosis 9 (5%) 49 (13%)
SVG target lesion location–lesion, n (%)
 Ostial 38 (17%) 118 (25%) 0.0003
 Body 176 (78%) 297 (64%)
 Anastomosis 10 (4%) 49 (11%)
Pre-stenting target lesion TIMI-flow–subject, n (%)
 0 1 (1%) 4 (1%) 1.00
 1 4 (2%) 16 (4%) 0.24
 2 22 (12%) 66 (17%) 0.12
 3 160 (86%) 309 (79%) 0.0361
Pre-stenting target lesion TIMI-flow–lesion, n (%)
 0 1 (0%) 4 (1%) 0.17
 1 7 (3%) 17 (4%)
 2 26 (10%) 69 (16%)
 3 214 (86%) 350 (80%)
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Stent-Only (n=185 Subjects and 
248 Lesions)
Balloon-Stent (n=390 Subjects and 
440 Lesions) P Value
Post-stenting target lesion TIMI-flow–subject, n (%)
 0 1 (1%) 1 (0%) 0.54
 1 0 (0%) 0 (0%) N/A
 2 4 (2%) 6 (2%) 0.73
 3 182 (98%) 385 (99%) 0.72
Post-stenting target lesion TIMI-flow–lesion, n (%)
 0 1 (0%) 0 (0%) 0.39
 1 0 (0%) 0 (0%)
 2 4 (2%) 6 (1%)
 3 243 (98%) 434 (99%)
Lesion severity, mean % (SD)
 Pre-PCI 80.71 (10.91) 86.13 (10.02) <0.0001
 Post-PCI 0.38 (1.60) 0.84 (2.96) 0.19
Thrombus present–subject, n (%) 27 (15%) 55 (14%) 0.87
Thrombus present–lesion, n (%) 31 (13%) 58 (13%) 0.80
Arterial access, n (%)
 Femoral 167 (90%) 362 (93%) 0.46
 Radial 17 (9%) 25 (6%)
 Other 1 (1%) 3 (1%)
Target lesion stent diameter, mm 3.41±0.52 3.39±0.53 0.68
Target lesion first balloon diameter, mm–437 
lesions in 390 subjects N/A 2.75±0.79 N/A
Target lesion second balloon diameter, if used, 
mm–171 lesions in 156 subjects N/A 3.36±0.78 N/A
Total length of stents in target lesions per 
patient, mm 25.46±16.92 27.47±19.36 0.19
Number of balloons used in target lesions per 
subject N/A 1.72±1.05 N/A
Anticoagulant, n (%)
 Heparin 105 (57%) 228 (58%) 0.70
 Bivalirudin 88 (48%) 163 (42%) 0.19
 GP2b3a 32 (17%) 52 (13%) 0.21
Highest ACT 312.03±73.04 303.60±87.01 0.23
Angiographic success–subject, n (%) 185 (100%) 388 (99%) 1.00
Angiographic success–lesion, n (%) 247 (100%) 438 (100%) 1.00
Any procedural complication, n (%) 6 (3%) 25 (6%) 0.12
No reflow, n (%) 5 (3%) 14 (4%) 0.58
Periprocedural MI, n (%) 5 (3%) 23 (6%) 0.10
ACT indicates activated clotting time; BMS, bare metal stent; DES, drug-eluting stent; LAD, left anterior descending; MI, myocardial infarction; 
N/A, not any; OM, obtuse marginal branch; PCI, percutaneous coronary intervention; RCA/PDA, right coronary artery or posterior descending 
artery; SVG, saphenous vein graft; and TIMI, Thrombolysis in Myocardial Infarction.
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Table 5.
Medication Use During Follow-Up of the Study Patients
Medications During Follow-Up Stent-Only (n=185) Balloon-Stent (n=390) P Value
Patients with a 12-mo visit, n (%) 164 (89%) 345 (88%) 0.95
Aspirin at 12 mo, n (%) 154 (94%) 319 (92%) 0.46
P2Y12 inhibitor at 12 mo, n (%) 146 (89%) 305 (88%) 0.76
 Clopidogrel at 12 mo, n (%) 137 (84%) 283 (82%) 0.62
 Ticlopidine at 12 mo, n (%) 0 (0%) 1 (0%) 1.00
 Prasugrel at 12 mo, n (%) 7 (4%) 13 (4%) 0.78
 Other at 12 mo, n (%) 2 (1%) 9 (3%) 0.52
Statin at 12 mo, n (%) 154 (94%) 319 (92%) 0.46
Number of subjects who had a 24-month visit, n (%) 134 (72%) 257 (66%) 0.12
Aspirin at 24 mo, n (%) 125 (93%) 229 (89%) 0.18
P2Y12 inhibitor at 24 mo, n (%) 75 (56%) 151 (59%) 0.60
 Clopidogrel at 24 mo, n (%) 71 (53%) 136 (53%) 0.99
 Ticlopidine at 24 mo, n (%) 0 (0%) 0 (0%) N/A
 Prasugrel at 24 mo, n (%) 2 (1%) 7 (3%) 0.72
 Other at 24 mo, n (%) 2 (1%) 8 (3%) 0.50
Statin at 24 mo, n (%) 124 (93%) 234 (91%) 0.62
Number of subjects who had a 36-mo visit, n (%) 91 (49%) 164 (42%) 0.11
Aspirin at 36 mo, n (%) 81 (89%) 132 (80%) 0.13
P2Y12 inhibitor at 36 mo, n (%) 47 (52%) 68 (41%) 0.15
 Clopidogrel at 36 mo, n (%) 41 (45%) 60 (37%) 0.23
 Ticlopidine at 36 mo, n (%) 0 (0%) 0 (0%) N/A
 Prasugrel at 36 mo, n (%) 2 (2%) 6 (4%) 0.71
 Other at 36 mo, n (%) 4 (4%) 2 (1%) 0.19
Statin at 36 mo, n (%) 81 (89%) 144 (88%) 0.85
N/A indicates not any.
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Table 6.
Multivariate Analysis for Time to TVF at Entire Follow-Up
Characteristic HR (95% CI) P Value
Balloon-stent balloon use 0.84 (0.63–1.13) 0.24
Age 1.00 (0.98–1.02) 0.78
Diabetes mellitus 1.09 (0.81–1.46) 0.57
>1 target lesions 1.60 (1.12–2.29) 0.0097
Years since CABG 1.03 (1.00–1.05) 0.0382
History of CHF 1.26 (0.94–1.69) 0.12
PCI for ACS 1.17 (0.87–1.58) 0.30
Presence of thrombus 0.83 (0.55–1.25) 0.37
Baseline TIMI-3 flow 0.56 (0.40–0.78) 0.0006
EPD used 0.99 (0.72–1.36) 0.96
TVF is a composite of cardiac death, target vessel myocardial infarction, and target vessel revascularization. ACS indicates acute coronary 
syndrome; CABG, coronary artery bypass grafting; CHF, congestive heart failure; EPD, embolic protection device; HR, hazard ratio; PCI, 
percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction; and TVF, target vessel failure.
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